Table 1.
Patient baseline characteristics according to derivation and validation set
| Characteristics | Set | P-value | |
|---|---|---|---|
| Derivation (n = 196) | Validation (n = 197) | ||
| Age (average, years) | 54 | 54 | 0.99 |
| Female Gender, n (%) | 71 (36 %) | 71 (36 %) | 0.97 |
| BMI (kg/m2) | 26.7 | 27.6 | 0.08 |
| BMI ≥ 25, n (%) | 126 (64 %) | 122 (62 %) | 0.94 |
| Pre-existing diabetes | 17 (9 %) | 19 (10 %) | 0.74 |
| Mean glucose (mmol/L) | 7.4 | 7.0 | 0.30 |
| ECOG performance status, n (%) | |||
| 0–1 | 171 (87 %) | 168 (85 %) | 0.57 |
| 2–3 | 25 (13 %) | 29 (15 %) | |
| Proportion of patients on Dexamethasone, n (%) | 187 (95 %) | 172 (88 %) | 0.01 |
| Mean TWM dexamethasone dose | 4.5 | 4.0 | 0.03 |
| Extent of surgery, n (%) | |||
| Subtotal | 35 (18 %) | 37 (19 %) | 0.76 |
| Partial | 120 (61 %) | 122 (62 %) | |
| Biopsy | 40 (20 %) | 38 (19 %) | |
| Unknown | 1 (1 %) | – | |
| Radiation dose, n (%) | |||
| 60/30 | 160 (82 %) | 172 (87 %) | 0.16 |
| 54/30 | 26 (13 %) | 13 (7 %) | |
| Other | 10 (5 %) | 12 (6 %) | |
| Temozolomide n (%) | 196 (100 %) | 197 (100 %) | – |
| Concurrent | 41 (21 %) | 36 (18 %) | 0.51 |
| Concurrent & adjuvant | 155 (79 %) | 161 (82 %) | |
| Adjuvant cycle number | 4 | 3 | 0.77 |
| Metformin use | 27 (14 %) | 20 (10 %) | 0.27 |
| Hyperglycemia interventions | 43 (22 %) | 30 (15 %) | 0.09 |
| Salvage treatment, n (%) | 114 (58 %) | 119 (60 %) | 0.65 |
| Hospital admission, n (%) | 86 (44 %) | 82 (42 %) | 0.65 |
| Acute infection, n (%) | 44 (22 %) | 53 (27 %) | 0.31 |
BMI body mass index, ECOG eastern cooperative oncology group, TWM time weighted mean